Voyager Therapeutics (VYGR) Return on Capital Employed (2015 - 2026)

Voyager Therapeutics has disclosed Return on Capital Employed across 12 years of filings, most recently posting 58.36% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 58.36%, down 2778.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 58.36% (down 2778.0% YoY), and the FY2025 annual result was 44.52%, down 1869.0% from the prior year.
• Return on Capital Employed came in at 58.36% for Q1 2026 at Voyager Therapeutics, down from 54.09% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 40.98% in Q1 2023 to a low of 64.63% in Q1 2022.
• The 5-year median for Return on Capital Employed is 30.58% (2025), against an average of 25.2%.
• Across the five-year window, Return on Capital Employed sank 7630 bps in 2022 and surged 10562 bps in 2023, its largest moves.
• Voyager Therapeutics' Return on Capital Employed stood at 51.7% in 2022, then jumped by 121 bps to 10.87% in 2023, then slumped by 313 bps to 23.15% in 2024, then slumped by 134 bps to 54.09% in 2025, then slipped by 8 bps to 58.36% in 2026.
• The last three Return on Capital Employed figures came in at 58.36% (Q1 2026), 54.09% (Q4 2025), and 51.99% (Q3 2025), per Business Quant data.